Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada.
Canada
atezolizumab
cost
immunotherapy
non-small cell lung cancer
recurrence
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
19
04
2024
revised:
29
05
2024
accepted:
05
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
epublish
Résumé
This epidemiological model forecasted reductions in recurrences and recurrence treatment cost savings with adjuvant atezolizumab vs best supportive care among Canadians with stage II-IIIA non-small cell lung cancer (NSCLC) at national and provincial levels. The population had resected, programmed cell death 1 ligand 1 (PD-L1)-high (≥50%),
Identifiants
pubmed: 38920734
pii: curroncol31060251
doi: 10.3390/curroncol31060251
doi:
Substances chimiques
atezolizumab
52CMI0WC3Y
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3301-3310Subventions
Organisme : F. Hoffmann-La Roche Ltd
ID : N/A